Affordability, politics will dictate health insurance trends in 2017

This year is likely to be a “period of uncertainty and flux” for health insurers due to the political debate on repealing the Affordable Care Act (ACA), according to Deloitte’s 2017 health insurance industry outlook.

“Political change and disruption, market disruption prompted by political change is likely to be the number one issue not just on January 1, obviously before the January 20 inauguration Day and probably too early in the year to have anything approaching an understanding of what sort of statutory and regulatory change from Washington DC will come to health plans,” said Deloitte’s U.S. health plan practice leader Greg Scott.

Beyond the ACA concerns, Scott expects affordability to dominate discussions between providers and insurers. While healthcare spending continues to grow, consumers are being asked to shoulder more of the costs, which is a trend insurers shouldn’t ignore, according to Scott.

“The share of the burden of American healthcare, the costs of American healthcare, that has shifted over recent years to the consumers, is really amazing,” he said.

For more on how the shift to value-based care and consumer priorities will affect the insurance industry in the next year, read the full interview below:  

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.